Video

Practical Considerations for Selection of PSMA-PET Tracers

Author(s):

Phillip Koo, MD,Michael S. Cookson, MD, MMHC

Experts discuss practical considerations on selection among available PSMA-PET tracer options for prostate cancer imaging, including regional availability, scheduling, and preparation requirements.

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Vanita Gaglani, RPT, answers a question during a video interview
Man talking with doctor | Image Credit: © DragonImages - stock.adobe.com
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
Related Content
Trial of 64Cu/67Cu-SAR-bisPSMA in mCRPC progresses to dose expansion phase
March 5th 2025

Trial of 64Cu/67Cu-SAR-bisPSMA in mCRPC progresses to dose expansion phase

Hannah Clarke
The safety review committee recommended that the phase 2 portion proceed with the 8 GBq dose.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
FDA updates in urology: February 2025
March 3rd 2025

FDA updates in urology: February 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from February 2025.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer
February 25th 2025

Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer

Hannah Clarke
Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.
Phase 1/2 trial launches of first-in-class RIPTAC therapeutic in mCRPC
February 24th 2025

Phase 1/2 trial launches of first-in-class RIPTAC therapeutic in mCRPC

Hannah Clarke
The trial plans to enroll up to 80 adult patients with mCRPC who have progressed on prior systemic therapies.
© 2025 MJH Life Sciences

All rights reserved.